VJOncology is committed to improving our service to you

ASCO 2020 | ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumors

VJOncology is committed to improving our service to you

Giuseppe Curigliano

Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, gives an overview of the ARROW study (NCT03037385), which was designed to evaluate the safety, tolerability and preliminary antineoplastic activity of pralsetinib in patients with medullary thyroid cancer, RET-altered non-small cell lung cancer (NSCLC) and other RET-altered solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter